Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Fig. 2

Investigator-assessed efficacy outcomes. A Overall response by TLS-risk group. B PFS by Kaplan–Meier estimates. Tick marks indicate patients with censored data. Abbreviations: CI, confidence interval; CR, complete response; CT, computed tomography; NE, not estimable; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TLS, tumor lysis syndrome. aTwo patients with a CR by CT scan are missing confirmatory bone marrow examinations and therefore are considered to have PR. bOne patient was not evaluable

Back to article page